Table 1.
Baseline characteristics of patients included in the study
| Characteristics | Total n = 1,420 |
Non-squamous NSCLC n = 983 |
Squamous NSCLC n = 437 |
|---|---|---|---|
| Sex | |||
| Male | 986 (69.4) | 633 (64.4) | 353 (80.8) |
| Median age, years (range) | 66 (35–91) | 65 (35–91) | 68 (44–91) |
| Patients aged ≥80 years | 116 (8.2) | 69 (7.0) | 47 (10.8) |
| Smoking status1 | |||
| Nonsmoker | 145 (10.2) | 122 (12.4) | 23 (5.3) |
| Former or current smoker | 1,272 (89.8) | 858 (87.6) | 414 (94.7) |
| ECOG PS at inclusion visit2 | |||
| 0 or 1 | 1,172 (82.9) | 829 (84.6) | 343 (79.2) |
| 2 | 192 (13.6) | 122 (12.4) | 70 (16.2) |
| 3 or 4 | 49 (3.5) | 29 (3.0) | 20 (4.6) |
| TNM classification at inclusion visit I–II* |
4 (0.3) | 2 (0.2) | 2 (0.2) |
| IIIA | 24 (1.7) | 11 (1.1) | 13 (3.0) |
| IIIB | 94 (6.6) | 31 (3.2) | 63 (14.1) |
| IV | 1298 (91.4) | 939 (95.5) | 359 (82.2) |
| Median number of metastatic sites, n (range) | 2 (0–8) | 2 (0–7) | 2 (0–8) |
| Patients with brain metastases | 282 (19.9) | 237 (24.1) | 45 (10.3) |
| Symptomatic brain metastases | 78 (5.5) | 68 (6.9) | 10 (2.3) |
| Treated brain metastases | 197 (13.9) | 165 (16.8) | 32 (7.3) |
| Patients with liver metastases | 235 (16.5) | 168 (17.1) | 67 (15.3) |
| Active autoimmune disease | 42 (3.0) | 29 (3.0) | 13 (3.0) |
All values are presented as n (%) unless stated otherwise.
1three missing value;
2seven missing values.
*likely understood as stage at diagnosis instead of stage at nivolumab initiation.
ECOG PS, Eastern Cooperative Oncology Group Performance Status; max, maximum; min, minimum; NSCLC, non-small cell lung cancer; TNM, tumor, nodes, metastasis.